tbuckley/cabot-search huggingface dataset:
Medical News
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Amer J of Digestive Disease, New York
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tidsskrift for den Norske Laegeforening, Oslo
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Health Care Financing Administration
Authors: W. L. Roper
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Information in Abstract and Table
Journal: JAMA Psychiatry (2015)

In the Original Article titled “Depression and Anxiety as Predictors of 2-Year Cardiac Events in Patients With Stable Coronary Artery Disease” published in the January 2008 issue of JAMA Psychiatry (then Archives of General Psychiatry) (2008;65[1]:62-71), incorrect unadjusted data appeared in the abstract and Table 3.The data that appeared in the abstract should have been as follows: “Of the 804 patients, 57 (7.1%)met the criteria for MDD [major depressive disorder] and 43 (5.3%) for GAD [generalized anxiety disorder] (11 [1.4%] had comorbidity);220(27.4%) had elevated BDI-II [Beck Depression Inventory II] scores (14), and 3 33(41.4%) had elevated HADS-A [Hospital Anxiety and Depression Scale] scores (8), with 21.1% overlap. Major depressive disorder (odds ratio [OR], 2.55;95%confidence interval [CI], 1.38-4.73),GAD(OR, 2.47; 95%CI, 1.23-4.97), elevated BDI-II (OR, 1.81; 95%CI, 1.20-2.73), elevated HADS-A score(OR, 1.66;95%CI, 1.12-2.47), and continuous standardized scores on the BDI-II (OR, 1.31; 95% CI, 1.05-1.62) and the HADS-A (OR, 1.43; 95% CI, 1.19-1.73) all predicted MACEs [major adverse cardiac events].” These ORs and 95% CIs should have also appeared in Table 3. Also, the covariate-adjusted ORs and 95% CIs in Table 3 should have been as follows: current MDD(OR, 2.34;95%CI, 1.18-4.63; P = .02); elevated depression symptoms (BDI-II score 14)(OR,1.63;95%CI,1.05-2.54;P = .03); continuous BDI-II score (OR, 1.19; 95%CI, 0.95-1.49; P = .14); GAD (OR, 2.46; 95% CI,1.14-5.30;P = .02); elevated anxiety symptoms(HADS-A score 8)(OR,1.54;95% CI, 1.00-2.38; P = .05); and continuous HADS-A score (OR, 1.42; 95% CI, 1.14-1.75;P = .001). This article was corrected online.
A NEWSPAPER FOR THE NERVOUS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NERVE INJURIES DUE TO ERRORS IN TECHNIC IN MAKING INTRAVENOUS ARSPHENAMIN INJECTIONS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstracts Appearing in JAMA Jan 7, 1974 to March 25,1974
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Population Issues and Women's Reproductive Health: An International Perspective
Authors: K. Miller
Journal: Annual Review of Public Health (1996)

This paper gives a brief overview of current world population or demographic issues, followed by a discussion of the ICPD proceedings and various notable aspects of the ICPD Programme of Action. It then focuses on six of the most pressing reproductive health concerns facing women today: gender inequalities, access to contraceptive services, sexually transmitted diseases (including HIV), maternal mortality, unsafe abortion, and adolescent pregnancy. Because the ICPD Programme of Action is intended to have far-reaching consequences for each of these issues, it is taken as a focal point of analysis.
Bioengineered Cardiac Grafts
Authors: Jonathan Leor, Sharon Aboulafia-Etzion, Ayelet Dar, Lilia Shapiro, Israel M. Barbash, Alexander Battler, Yosef Granot, Smadar Cohen
Journal: Circulation (2000)

Background —The myocardium is unable to regenerate because cardiomyocytes cannot replicate after injury. The heart is therefore an attractive target for tissue engineering to replace infarcted myocardium and enhance cardiac function. We tested the feasibility of bioengineering cardiac tissue within novel 3-dimensional (3D) scaffolds. Methods and Results —We isolated and grew fetal cardiac cells within 3D porous alginate scaffolds. The cell constructs were cultured for 4 days to evaluate viability and morphology before implantation. Light microscopy revealed that within 2 to 3 days in culture, the dissociated cardiac cells form distinctive, multicellular contracting aggregates within the scaffold pores. Seven days after myocardial infarction, rats were randomized to biograft implantation (n=6) or sham-operation (n=6) into the myocardial scar. Echocardiography study was performed before and 65±5 days after implantation to assess left ventricular (LV) remodeling and function. Hearts were harvested 9 weeks after implantation. Visual examination of the biograft revealed intensive neovascularization from the neighboring coronary network. Histological examination revealed the presence of myofibers embedded in collagen fibers and a large number of blood vessels. The specimens showed almost complete disappearance of the scaffold and good integration into the host. Although control animals developed significant LV dilatation accompanied by progressive deterioration in LV contractility, in the biograft-treated rats, attenuation of LV dilatation and no change in LV contractility were observed. Conclusions —Alginate scaffolds provide a conducive environment to facilitate the 3D culturing of cardiac cells. After implantation into the infarcted myocardium, the biografts stimulated intense neovascularization and attenuated LV dilatation and failure in experimental rats compared with controls. This strategy can be used for regeneration and healing of the infarcted myocardium.
RETROGRESSION IN NEW YORK CITY
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bcl-2 Antagonist ApoGossypol (NSC736630) Displays Single-Agent Activity in Bcl-2 Transgenic Mice and Has Superior Efficacy and Pharmacology with Less Toxicity Compared to Gossypol (NSC19048).
Authors: Shinichi Kitada, Lee Jia, Lori C. Coward, Greg S. Gorman, Patricia Noker, Maurizio Pellecchia, John C. Reed
Journal: Blood (2006)
Ifosfamide for intraocular lymphoma
Authors: E. Thiel, K. Jahnke, T. Wagner, N. E. Bechrakis, S. E. Coupland, A. Schmittel, L. Fischer, M. H. Foerster, A. Korfel
Journal: Journal of Clinical Oncology (2004)

1520 Background: Intraocular lymphoma (IOL) occurs as a manifestation of a primary central nervous system lymphoma (PCNSL) or as ocular involvement of a systemic lymphoma. The treatment of IOL has not yet been defined, since the data has been limited to small, usually retrospective treatment series or case reports. CNS relapse is the rule after local treatment modalities. Ifosfamide is administered intravenously (IV) or orally (PO) as the main metabolite of trofosfamide. Its penetration into the eye has never been evaluated but is assumed based on its ability to penetrate the CNS. Methods: We treated 4 patients (pts) with bilateral IOL confirmed by vitrectomy and/or chorioretinal biopsy. Patient (pt) 1, a 83-year-old woman with newly diagnosed primary IOL and multiple comorbidities, refused radiotherapy (RT). Pt 2, a 46-year-old man, had a PCNSL resistant to 3 chemotherapy regimens and relapsed after RT in both eyes. Pt 3, a 77-year-old man, had secondary IOL due to newly diagnosed immunocytoma. Pt 4, a 52-year-old man, had an intraocular relapse of PCNSL after high-dose methotrexate and RT. Pts 1 and 2 received either 150 mg or 400 mg/day of trofosfamide PO on days 1–5 followed by a five-day drug-free interval. Pts 3 and 4 received either 2,000 or 1,500 mg/m2/day of ifosfamide IV days 1–3. Concentrations of ifosfamide and its active metabolite, 4-hydroxy-ifosfamide, were measured in the serum and anterior chamber of the eye in pt 4. Results: According to fundoscopy, pts 1–3 achieved complete remission at 7+, 18 and 3+ months, which was accompanied by a significant increase in visual acuity (VA). Pt 4, who is still under treatment, had a partial remission after one cycle with VA normalization. The 4-hydroxy-ifosfamide concentration in the anterior chamber of the eye was 2.39 μmol/l (54 % of the corresponding serum concentration) directly after the 2-hour infusion. No significant therapy-related side effects were noted in all pts. Conclusions: Ifosfamide seems to be active in IOL with a favorable side effect profile. Trofosfamide can be administered on an outpatient basis. The eye was significantly penetrated by 4-hydroxy-ifosfamide. No significant financial relationships to disclose.
BOOK REVIEWS
Authors: N. B. FRIEDMAN
Journal: JNCI Journal of the National Cancer Institute (1993)

BOOK REVIEWS Get access Treatment of Pre-Cancerous Lesions and Early Breast Cancer Irving M. Ariel , Anthony C. Cahan , eds . Baltimore : Williams & Wilkins , 1993 . 346 pp., illus. $85. ISBN 0-683-00255-4 NEIL B. FRIEDMAN, M.D. NEIL B. FRIEDMAN, M.D. The Johns Hopkins Hospital and School of Medicine550 N. Broadway Suite 1001, Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 22, 17 November 1993, Pages 1862–1863, https://doi.org/10.1093/jnci/85.22.1862 Published: 17 November 1993
Whither Psychiatry
Authors: Peter D. King
Journal: JAMA (1974)

<h3>To the Editor.—</h3> In his editorial "Quo Vadis, Psychiatry?" the writer ends with the warning that "the need for psychiatry may soon become questionable." I find that hard to believe, treating some 50 patients a week, in addition to teaching, writing, research, and executive responsibilities in professional organizations. Most of my colleagues in psychiatry also seem to be quite busy professionally, while only internists and surgeons are busier than psychiatrists and pediatricians. It seems to me that the need for psychiatry is substantial. It is true that much remains to be understood, and there is diversity of opinion on diagnosis, treatment, pathogenesis, and etiology. But that is true in other branches of medicine, too. I agree that clinical skills and a scientific medical attitude are crucial to psychiatry, and in my experience most physicians, including psychiatrists, have those skills and attitudes. Further, I agree that all physicians should consider their
Abstract P297: Depressive Symptoms, Weight Gain and Risk of Obesity in U.S. Black Women
Authors: Edward A Ruiz-Narváez, Julie R Palmer, Hanna Gerlovin, Lauren A Wise, Lynn Rosenberg
Journal: Circulation (2016)

Background: Depression may lead to weight gain and obesity. Few prospective studies have examined the relation of depression to weight gain and obesity among African-American women, though obesity disproportionately affects this population. Methods: We assessed the association of depressive symptoms with weight gain and risk of obesity in the Black Women’s Health Study (BWHS), an ongoing prospective cohort study initiated in 1995. We included 22,240 non-obese women who completed the Center for Epidemiologic Studies Depression Scale (CES-D) in 1999 and followed them for weight change through 2013. We categorized depressive symptoms into CES-D &lt;16, 16-22, 23-32, and ≥33; values of ≥16 have a moderate to high sensitivity for major depression. We used generalized estimating equations to estimate mean weight change in relation to symptoms of depression and Cox regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between depressive symptoms and incident obesity. The basic multivariate model was adjusted for age, time period, height, antidepressants use, education, and marital status. To this model, we added lifestyle factors (dietary patterns, energy intake, exercise, hours of TV watching, smoking, and alcohol drinking) to assess whether the association of depressive symptoms with weight gain and obesity was independent of these factors. Results: Relative to CES-D &lt;16, mean weight-gain difference (95% CI) during 14 years of follow-up for CES-D 16-22, 23-32, and ≥33 were 0.88 kg (0.40, 1.36), 0.28 kg (-0.35, 0.90), and 1.15 kg (0.07, 2.22) (P-trend = 0.001), respectively. After adjustment for lifestyle factors, the respective differences decreased to 0.80 kg (0.32, 1.27), 0.15 kg (-0.48, 0.78), and 1.01 kg (-0.06, 2.09) (P-trend = 0.008). Participants with CES-D ≥16 had a mean weight difference of 0.73 kg (0.34, 1.12) in the basic multivariate model, and 0.62 kg (0.24, 1.01) in the lifestyle-adjusted model compared to subjects with CES-D &lt;16. Regarding incident obesity, in the basic multivariate model, HRs (95% CI) of obesity for CES-D 16-22, 23-32, and ≥33 were 1.17 (1.10, 1.25), 1.07 (0.98, 1.16), and 1.21 (1.08, 1.37) (P-trend &lt;0.0001), respectively. Corresponding HRs decreased to 1.14 (1.07, 1.22), 1.03 (0.95, 1.12), and 1.16 (1.03, 1.31) (P-trend = 0.001) after adjustment for dietary and physical activity covariates. Women with CES-D ≥16 had a HR of obesity equal to 1.14 (1.08, 1.20) in the basic multivariate model, and 1.11 (1.05, 1.17) in the lifestyle-adjusted model. Conclusions: Our results suggest a modest association of symptoms of depression with higher weight gain and risk of obesity. The association was attenuated but persisted after successive adjustment for lifestyle factors, suggesting an independent effect of depression on weight gain and obesity.
Tighten but do not discard
Authors: L. H. Roth
Journal: JAMA (1984)

ALTHOUGH the Hinckley verdict brought the insanity defense under attack, controversies about insanity have raged for a long time. Because the defense touches on the symbolic and practical functions of the criminal law (and ultimately on our individual, deeply held views about justice) it is not surprising that professional organizations, legislatures, and the informed public recommend differing pathways to reform. Reasonable men differ in their views about the insanity defense. While medicine as a whole has some role to play, the most important considerations are those of social policy and our moral sentiments about what is fair and just. In its 1982 Statement on the Insanity Defense, the American Psychiatric Association (APA) recommended a somewhat different future course than does the American Medical Association. However, it is important to note agreements between the positions of these two medical organizations. Both the AMA and the APA agree that the insanity defense